The call recaps Regeneron's Q4 2025 financials, outlines risks, clarifies forward-looking statements, and previews guidance, development programs, and regulatory matters, emphasizing non-GAAP measures and investor Q&A.

The company reported strong Q4 2025 financials with 32% global net sales growth for Dupixent, reaching $4.9 billion, and Ilea HD sales at $506 million in the US. Future plans include at least four FDA approvals, initiating 18 Phase 3 studies, and addressing biosimilar competition and patient affordability, aiming for continued growth and innovation in 2026.

The company outlines its strategic focus on maximizing leading brands, deploying capital through share repurchases, dividends, and business development to enhance shareholder value. It highlights significant pipeline progress across oncology, hematology, and immunology, including advancements in ophthalmology with C5 programs and innovative antibody therapies, aiming for competitive positioning and rapid clinical development to address various diseases.

Initial cat and bird phase studies showed cocktail allergen specific monopole effectiveness on ocular, nasal, respiratory, and skin endpoints. Phase 3 data for Cat Allergy will be presented at Quad AI, with a confirmatory study planned for H1. Severe food allergy treatment via transient live therapy achieved over 90% sustained IgE reduction, validating the approach. Next-generation treatments targeting Ig-producing cells are in development for broader applications, including oncology.

Regeneron's pipeline showcases significant progress in melanoma, lung cancer, myeloma, and rare diseases. Key updates include promising clinical data, pivotal trial readouts, and regulatory milestones. The company is simplifying myeloma treatment, developing novel GLP-1 combinations for obesity and hyperlipidemia, and advancing gene therapies for rare conditions. Pivotal studies and regulatory submissions are expected in 2023-2024, positioning Regeneron for transformative impacts in healthcare.

The fourth quarter of 2025 marked a successful year-end for the company, with market-leading brands driving sustainable growth. New medicines and indications were launched across various therapeutic areas and geographies. The retinal franchise, particularly LEOHD and IEO, saw significant net sales growth, driven by increased physician demand despite a decline in the overall anti-VEGF category. The company is poised for continued success in 2026, aiming to expand its portfolio and impact more patients' lives.

The innovative branded anti-VEGF segment faced a 12% decline in 2025, excluding Avastin and biosimilars. However, Ilea HD's enhanced label, dosing flexibility, and durability profile strengthened its market position, contributing nearly half of total anti-VEGF net sales. New real-world data showed patients on ongoing anti-VEGF therapy could extend treatment duration by almost four weeks upon switching to Ilea HD. The potential FDA approval of the PFI syringe aims to further enhance Ilea HD's convenience and profile, despite a 15% sequential decline in fourth-quarter US net sales.

The dialogue highlights robust sales growth in Q4, driven by successful product launches and strong market demand, with particular emphasis on expanding indications and treatment options for various diseases, setting a positive outlook for future commercial performance and patient treatment accessibility.

Regeneron reported Q4 2025 revenues of $3.9 billion, a 3% increase, driven by collaboration revenues and dupixent sales. The effective tax rate rose to 17%, and the company generated $4.1 billion in free cash flow, returning $3.8 billion to shareholders via repurchases and dividends, with a new quarterly dividend of $94 per share authorized.

The dialogue outlines financial projections for 2026, highlighting RD spend, SGNA investments, and capital expenditures. RD spend is expected to increase due to late-stage pipeline costs, including oncology and hematology studies, Factor 11 antibodies, and obesity programs. SGNA investments will support product launches and new molecule advancements. Gross margin and capital expenditures guidance reflects product mix changes and facility expansions.

A discussion on Regeneron's expected tax rate for 2026, highlighting the impact of a 2025 tax audit settlement, and the company's commitment to investing in its pipeline for patient advancements and shareholder value. The dialogue also touches on the timing of data readouts for advanced melanoma treatments, with an estimated first-half 2026 release.

Highlights Dupixent's remarkable efficacy and safety, emphasizing its unique pathway targeting allergic diseases without general immunosuppression, and mentions promising follow-on opportunities in immunology.

The dialogue addresses expectations for the primary endpoint in a clinical study focusing on frontline metastatic melanoma, emphasizing the study's power to detect a benefit similar to or better than the current standard of care. It also clarifies that PD-L1 expression levels are being screened but not used as an inclusion or exclusion criterion, aiming to reflect the true population of first-line advanced mononomial patients.

The dialogue discusses the company's RD strategy, emphasizing the expansion of focus areas beyond oncology to include Ini and ophthalmology, highlighting their strategic importance.

Discusses disappointment with industry's lack of innovation, emphasizing the company's commitment to using genetics and AI to discover new drugs for various therapeutic areas, ensuring a balanced approach while prioritizing genetic validation and advanced technologies for breakthroughs.

A biotech company discusses advancements in creating a superior version of Dupixent, utilizing advanced antibody generation technology. The new molecule shows potential benefits, including longer duration of action, and will be tested in clinical trials. The development aligns with an existing alliance, promising collaborative efforts for full-scale production if successful.

Discusses the differentiation in GA treatment programs, emphasizing systemic and local blockade approaches, potential for visual acuity benefits, and improved safety profiles compared to existing therapies. Highlights the study's endpoints and the exploration of monotherapy and combination therapies for enhanced patient outcomes.

The dialogue discusses IHD's growth trends, emphasizing the impact of label enhancements and the potential approval of a prefrontal syringe. It highlights the convenience factor for offices and its role in increasing demand for IHD, indicating a tipping point for ophthalmologist adoption.

The discussion focuses on the innovative co-formulation of a GLP drug with cholesterol-lowering properties into a single auto-injector, highlighting the unique formulation capabilities that enable this delivery method. The development offers a potential dual benefit for obesity patients, addressing both weight loss and cardiovascular risk, with plans to advance the clinical program.

The discussion focuses on contrasting small molecules with antibodies, particularly in the context of Factor 11 inhibitors. The emphasis is on the potential advantages of antibodies, including improved specificity, efficacy, and safety profiles, aiming for reduced bleeding risks and more convenient dosing schedules compared to small molecule alternatives.

The dialogue highlights the confidence in advancing GLP-1 GP to global Phase 3 trials due to its unique combination with PCSK9, offering significant LDL reduction and cardiovascular benefits. This differentiation positions the asset beyond current weight loss-focused competitors, aiming to provide a comprehensive solution for obesity and hyperlipidemia, potentially revolutionizing patient care and reducing cardiovascular disease.